| 生物活性 | |||
|---|---|---|---|
| 描述 | FHD-286 is a selective, orally administered inhibitor of the SMARCA4/SMARCA2 ATPase activities of BRG1 and BRM. FHD-286 is being investigated for potential therapeutic applications in BAF (BRG1/BRM-associated factor)-related disorders such as acute myeloid leukemia[1]. | ||
| 实验方案 | |||
|---|---|---|---|
| 1mg | 5mg | 10mg | |
|
1 mM 5 mM 10 mM |
1.78mL 0.36mL 0.18mL |
8.89mL 1.78mL 0.89mL |
17.77mL 3.55mL 1.78mL |
| 参考文献 |
|---|